Brief: Calliditas Therapeutics Establishes A U.S. At-The-Market Program
28/06/2022 23:30
June 28 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* CALLIDITAS THERAPEUTICS ESTABLISHES A U.S. AT-THE-MARKET
PROGRAM
* CALLIDITAS THERAPEUTICS AB - FILED SEC REGISTRATION
STATEMENT
INCLUDING A PROSPECTUS RELATING TO A U.S. AT--MARKET FRAMEWORK
OF UP TO $75 MILLION
Source text for Eikon: ID:nPn4HznB8a
Further company coverage: CALTX.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations